Revolution Medicines stock

RVMD · NASDAQ · USD

Compare Revolution Medicines
$162.69Change from previous close: −2.50%Absolute change: −$4.18

Close · November 17, 2026

Price history

+136.25% over the period

1 year: from $69.14 (November 17, 2025) to $163.35 (November 17, 2026), +136.25%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$163.35
October 30, 2026$191.31
September 30, 2026$205.26
August 31, 2026$205.57
July 31, 2026$187.53
June 30, 2026$187.28
May 29, 2026$157.48
April 30, 2026$144.12
March 31, 2026$97.25
February 27, 2026$102.02
January 30, 2026$96.95
December 31, 2025$79.65
November 28, 2025$77.76
November 17, 2025$69.14

At a glance

  • The company

    Clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers

  • Latest results

    Quarter to September 30, 2026 · EPS -$1.90 (estimate -$2.35)

TickerLandia's take on Revolution Medicines

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$67.27
52-wk high$224.31

−27.47% from the 52-week high

Analysts · 24 analysts

Average target$274.76+68.89% vs. price

Buy 23 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Revolution Medicines

Compared with similar companies: very high price, very low earnings stability, and very low profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Revolution Medicines is pricier than similar companies

Revolution Medicines's Price/book: 15.5, +92% against the median of a group of 11 similar companies (8.06).

Compared with 11 similar companies

Revolution Medicines's metrics compared with similar companies
MetricRevolution MedicinesPosition in the groupBand
Operating margin-853.0%Low
ROE-93.6%Low
Debt/equity0.50Middle
Price/book15.5High
Net margin0.0%Middle

Grey band: the middle half of the group; tick: the median; dot: Revolution Medicines. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$0

Latest quarter · Q2 2026

Net income

-$644.37M

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$37.27B
EPS
-$8.92
Volume
2.65M
Daily trading
€400.23M
Dividend yield
0.00%

How Revolution Medicines is changing

All results
  • Shares outstanding up 246.5% in 5 years

  • Profitable in 0 of 5 fiscal years

Returns

Revolution Medicines returns

$1,000 invested in Revolution Medicines 5 years ago, on November 17, 2021, would be worth $5,271 today: +427.09% in total, +39.44% per year. This is the price return only: dividends are excluded.

PeriodRevolution MedicinesS&P 500$1,000 becomes
1 month−10.32%−3.17%$897
6 months+11.69%+0.11%$1,117
Year to date+105.08%+8.34%$2,051
1 year+136.25%+11.15%$2,363
3 years+665.80%+64.30%$7,658
5 years+427.09%+58.18%$5,271

Over the last 6 months it has done better than 41% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Revolution Medicines: technical analysis

Revolution Medicines shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 26.4% below its all-time closing high ($221.15, August 27, 2026).

Trend
No clear trend
RSI (14 sessions)
35
Between 30 and 70
vs 200-session average
+1.33%

Active signals

  • Close below the low of the previous 55 sessions.

    since November 13, 2026

Support and resistance

Price areas where Revolution Medicines has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$212.23+30.45%4 touches, last on November 5, 2026
  2. Resistance$195.77+20.33%3 touches, last on August 26, 2026
  3. Resistance$177.62+9.18%4 touches, last on October 16, 2026
  4. Last price$162.69
  5. Support$150.71−7.36%2 touches, last on May 6, 2026
  6. Support$141.22−13.20%2 touches, last on June 10, 2026
  7. Support$100.29−38.36%2 touches, last on April 2, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.30
Volatility (60 sessions, annualised)
52.4%
Largest fall in the last year
−26.43%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Revolution Medicines: seasonality

Average monthly price change over 7 years

+3.5%Jan+0.5%Feb−3.2%Mar+11.4%Apr−1.5%May+6.4%Jun−0.0%Jul+6.5%Aug+3.2%Sep+0.7%Oct+18.8%Nov−2.7%Dec

Over the last 7 years, the strongest month for Revolution Medicines has been November: +18.84% on average, positive in 5 years out of 6. The weakest has been March: −3.18% on average, positive in 3 years out of 7.

Show chart data
MonthAverageMedianPositive years
January+3.48%+2.32%3 of 6
February+0.45%+2.65%4 of 6
March−3.18%−4.68%3 of 7
April+11.41%+14.20%5 of 7
May−1.55%−1.76%3 of 7
June+6.36%+6.12%6 of 7
July−0.04%+0.13%4 of 7
August+6.51%+1.88%5 of 7
September+3.25%−0.15%3 of 7
October+0.74%+2.74%4 of 7
November+18.84%+17.13%5 of 6
December−2.72%−4.01%3 of 6

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Revolution Medicines and its competitors

Revolution Medicines, Inc. has been headquartered in Redwood City, California, since it was incorporated in 2014. The clinical-stage precision oncology company develops targeted therapies for RAS-addicted cancers. Its pipeline is built around RAS(ON) inhibitors that bind RAS variants and can be used alone or in combination with other RAS(ON) inhibitors, RAS companion inhibitors or other therapeutic agents.

Headquarters
Redwood City, United States
Employees
883
Founded
2014
Chief executive
Mark Goldsmith
Revolution Medicines and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Revolution MedicinesRVMD$37.27B-853.0%—+11.69%
Royalty PharmaRPRX$39.4B64.4%45.4+29.95%
BeOne MedicinesONC$46.98B17.8%52.7+40.91%
Roivant SciencesROIV$28.64B-3,226.3%—+32.16%
InsmedINSM$26.96B-41.7%—+11.65%
IncyteINCY$24.36B32.2%61.0+24.95%

Same industry or related industries, similar size. Compare Revolution Medicines with its competitors · Full profile